Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents

about

Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents

Item

http://www.wikidata.org/entity/Q57822338

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 11 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@en

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@nl

type

Item

label

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@en

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@nl

prefLabel

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@en

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@nl

P1476

Acyloxybenzyl and Alkoxyalkyl ...... rial and Antitubercular Agents

@en

P2093

Charlotte Courtens

http://www.w3.org/2001/XMLSchema#string

Guy Caljon

http://www.w3.org/2001/XMLSchema#string

Martijn Risseeuw

http://www.w3.org/2001/XMLSchema#string

P2860

Artemisinin Resistance in Plasmodium falciparum Malaria

Synthesis of nucleoside phosphate and phosphonate prodrugs

Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase

Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways

Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.

Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.

Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.

Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.

Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.

Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.

P304

986-989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.8B00223

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Serge Van Calenbergh

Paul Cos

P577

2018-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30344904

http://www.w3.org/2001/XMLSchema#string

P932

6187408

http://www.w3.org/2001/XMLSchema#string